Methodology of the Cardiovascular Health and Age-Related Maculopathy (CHARM) Study
- PMID: 15370549
- DOI: 10.1080/09286580490514469
Methodology of the Cardiovascular Health and Age-Related Maculopathy (CHARM) Study
Abstract
Age-related macular degeneration (AMD) is responsible for the majority of visual impairment in the Western world. Epidemiological studies examining risk factors for AMD are needed to develop strategies for the prevention of blindness from this condition. A number of potentially modifiable risk factors for AMD have been identified; however, only smoking has been a consistent risk factor across the numerous studies. A growing body of evidence suggests that AMD and cardiovascular disease may have common risk factors. The Cardiovascular Health and Age Related Maculopathy (CHARM) Study was established to examine the risk factors for AMD and its progression, in particular risk factors associated with cardiovascular disease. Examining risk factors for prevalent AMD, cases with AMD were compared with age and gender matched controls with no AMD features. For the assessment of AMD progression, the study examined in 2001 and 2002 those participants with early AMD, or age-related maculopathy (ARM), who had undergone baseline examination between 1992 and 1995 and compared the characteristics of those who had progression of AMD with those who did not. The CHARM study involved both ophthalmic and cardiovascular examinations. Standardised clinical eye examination and grading of the macular stereo photographs were used to determine the AMD status and progression. To examine cardiovascular status, carotid artery ultrasound imaging analysis of systemic arterial compliance, augmentation index and pulse wave velocity were performed. The traditional and novel risk factors for CVD such as levels of glucose, cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, fibrinogen, C-reactive protein, immunoglobulins A and M, homocysteine, oxidized LDL and the exposure to the Chlamydia Pneumonia infection were determined. DNA was collected for apolipoprotein E genotyping. The present paper outlines the primary aims of the CHARM study, the methodology involved and the recruitment results.
Similar articles
-
Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study.Ophthalmology. 2007 Jun;114(6):1143-50. doi: 10.1016/j.ophtha.2006.09.033. Epub 2007 Feb 1. Ophthalmology. 2007. PMID: 17275090
-
The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study.Ophthalmology. 2003 Jun;110(6):1273-80. doi: 10.1016/S0161-6420(03)00599-2. Ophthalmology. 2003. PMID: 12799274
-
Risk factors for incident age-related macular degeneration: pooled findings from 3 continents.Ophthalmology. 2004 Jul;111(7):1280-7. doi: 10.1016/j.ophtha.2003.11.010. Ophthalmology. 2004. PMID: 15234127
-
Epidemiology of age-related macular degeneration.Mol Vis. 1999 Nov 3;5:26. Mol Vis. 1999. PMID: 10562650 Review.
-
The epidemiology of age-related macular degeneration.Am J Ophthalmol. 2004 Mar;137(3):486-95. doi: 10.1016/j.ajo.2003.11.069. Am J Ophthalmol. 2004. PMID: 15013873 Review.
Cited by
-
Novel measures of cardiovascular health and its association with prevalence and progression of age-related macular degeneration: the CHARM Study.BMC Ophthalmol. 2008 Dec 22;8:25. doi: 10.1186/1471-2415-8-25. BMC Ophthalmol. 2008. PMID: 19102747 Free PMC article.
-
Risk factors for age-related maculopathy.J Ophthalmol. 2009;2009:360764. doi: 10.1155/2009/360764. Epub 2009 Sep 6. J Ophthalmol. 2009. PMID: 20339564 Free PMC article.
-
Can HMG Co-A reductase inhibitors ("statins") slow the progression of age-related macular degeneration? The age-related maculopathy statin study (ARMSS).Clin Interv Aging. 2008;3(3):581-93. doi: 10.2147/cia.s2748. Clin Interv Aging. 2008. PMID: 18982929 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials